📰 Sedation Scale News
Sedation Scale News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sedation Scale. Real-time updates on events, politics, business and more.
September 20, 2023
SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the...
September 20, 2023
Seelos Therapeutics, Inc. announced top line data demonstrating clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind,...
January 6, 2023
Investegate announcements from atai Life Sciences, atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 6, 2023
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "the Company"), a clinical-stage biopharmaceutical company focused on mental health, announced that,
January 6, 2023
Atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant DepressionNEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental h...
October 25, 2022
Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).Last patient...
October 25, 2022
Investegate announcements from atai Life Sciences, atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
October 25, 2022
Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).Last patient expected to be dosed this week, with the total number
November 22, 2021
Abstract In this second article of a seven-part series on critical care medicine, we discuss patient assessment. The assessment process must consider the
January 11, 2021
email article Acute brain dysfunction -- coma or delirium -- occurred frequently and was prolonged in critically ill COVID-19 patients, a large multicenter cohort study showed. Of more than 2,000 COVID-19 ICU patients in 14 countries, 82% were comatose for a median of 10 days, reported Rafael Badenes, MD, PhD, of the University of Valencia in Spain, and co-authors in Lancet Respiratory Medicine. For the 55% showing delirium, the median duration was 3 days. Acute brain dysfunction las...